Imidapril

Drug Profile

Imidapril

Alternative Names: Novarok; SH 6366; TA 6366; Tanatril

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer G.L. Pharma; Gerolymatos Group; Mitsubishi Tanabe Pharma Corporation; Trinity-Chiesi Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Imidazolidines; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diabetic nephropathies

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 03 Aug 2005 Xanodyne Pharmaceuticals has acquired the pharmaceutical assets of aaiPharma
  • 15 Feb 2003 Phase-II clinical trials in Hypertension in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top